Aldea Pharmaceuticals, based in Redwood City, CA, pioneers novel therapeutics to treat aldehyde metabolism disorders. Its lead drug candidate, AD-6626, activates an enzyme that accelerates metabolism that may help quickly sober up emergency room highly intoxicated patients. The company is also conducting a study of the drug in oral form against a rare genetic disease of bone marrow, known as Faconi’s anemia. This Series B financing will be used to advance AD-6626 into clinical trials, including evaluating proof-of concept for the treatment of subjects with acute alcohol intoxication and funding subsequent Phase 2 trials of intravenous (IV) AD-6626 in an emergency room setting.
We are very delighted to have played a role in Aldea’s endeavor of finding innovative cures for patients, and wish Aldea continued success!